TY - JOUR
T1 - Untargeted Metabolomic Plasma Profiling of Emirati Dialysis Patients with Diabetes Versus Non-Diabetic
T2 - A Pilot Study
AU - Banimfreg, Bayan Hassan
AU - Alshraideh, Hussam
AU - Shamayleh, Abdulrahim
AU - Guella, Adnane
AU - Semreen, Mohammad Harb
AU - Bataineh, Mohammad Tahseen Al
AU - Soares, Nelson C.
N1 - Funding Information:
Funding: This research was funded by internal funds provided by the American University of Sharjah (Grant code: FRG20-M-E108) and also funded by the University of Sharjah (Grant code: 1901090253, 1701090226).
Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/7
Y1 - 2022/7
N2 - Diabetic kidney disease (DKD) is a severe irreversible complication of diabetes mellitus that further disturbs glucose metabolism. Identifying metabolic changes in the blood may provide early insight into DKD pathogenesis. This study aims to determine blood biomarkers differentiating DKD from non-diabetic kidney disease in the Emirati population utilizing the LC-MS/MS platform. Blood samples were collected from hemodialysis subjects with and without diabetes to detect indicators of pathological changes using an untargeted metabolomics approach. Metabolic profiles were analyzed based on clinically confirmed diabetic status and current HbA1c values. Five differentially significant metabolites were identified based on the clinically confirmed diabetic status, including hydroxyprogesterone and 3,4-Dihydroxymandelic acid. Similarly, we identified seven metabolites with apparent differences between Dialysis Diabetic (DD) and Dialysis non-Diabetic (DND) groups, including isovalerylglycine based on HbA1c values. Likewise, the top three metabolic pathways, including Tyrosine metabolism, were identified following the clinically confirmed diabetic status. As a result, nine different metabolites were enriched in the identified metabolic pathways, such as 3,4-Dihydroxymandelic acid. As a result, eleven different metabolites were enriched, including Glycerol. This study provides an insight into blood metabolic changes related to DKD that may lead to more effective management strategies.
AB - Diabetic kidney disease (DKD) is a severe irreversible complication of diabetes mellitus that further disturbs glucose metabolism. Identifying metabolic changes in the blood may provide early insight into DKD pathogenesis. This study aims to determine blood biomarkers differentiating DKD from non-diabetic kidney disease in the Emirati population utilizing the LC-MS/MS platform. Blood samples were collected from hemodialysis subjects with and without diabetes to detect indicators of pathological changes using an untargeted metabolomics approach. Metabolic profiles were analyzed based on clinically confirmed diabetic status and current HbA1c values. Five differentially significant metabolites were identified based on the clinically confirmed diabetic status, including hydroxyprogesterone and 3,4-Dihydroxymandelic acid. Similarly, we identified seven metabolites with apparent differences between Dialysis Diabetic (DD) and Dialysis non-Diabetic (DND) groups, including isovalerylglycine based on HbA1c values. Likewise, the top three metabolic pathways, including Tyrosine metabolism, were identified following the clinically confirmed diabetic status. As a result, nine different metabolites were enriched in the identified metabolic pathways, such as 3,4-Dihydroxymandelic acid. As a result, eleven different metabolites were enriched, including Glycerol. This study provides an insight into blood metabolic changes related to DKD that may lead to more effective management strategies.
KW - diabetic kidney disease
KW - hemodialysis
KW - LC-MS/MS
KW - untargeted metabolomics
UR - http://www.scopus.com/inward/record.url?scp=85133721151&partnerID=8YFLogxK
U2 - 10.3390/biom12070962
DO - 10.3390/biom12070962
M3 - Article
C2 - 35883517
AN - SCOPUS:85133721151
SN - 2218-273X
VL - 12
JO - Biomolecules
JF - Biomolecules
IS - 7
M1 - 962
ER -
